1593269-74-9

Basic information

• Product Name: tert-butyl 2-(4-{[{[2-phenyl-5-(dimethylcarbamoyl)-1,3-oxazol-4-yl]methyl}(furan-2-ylmethyl)amino]methyl}-2,6-dimethylphenoxy)-2-methylpropanoate
• Synonyms: tert-butyl 2-(4-{[{[2-phenyl-5-(dimethylcarbamoyl)-1,3-oxazol-4-yl]methyl}(furan-2-ylmethyl)amino]methyl}-2,6-dimethylphenoxy)-2-methylpropanoate
• CAS NO: 1593269-74-9
• Molecular Weight: 560.69
• Mol File: 1593269-74-9.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(4-{[{[2-phenyl-5-(dimethylcarbamoyl)-1,3-oxazol-4-yl]methyl}(furan-2-ylmethyl)amino]methyl}-2,6-dimethylphenoxy)-2-methylpropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(4-{[{[2-phenyl-5-(dimethylcarbamoyl)-1,3-oxazol-4-yl]methyl}(furan-2-ylmethyl)amino]methyl}-2,6-dimethylphenoxy)-2-methylpropanoate(1593269-74-9)
• EPA Substance Registry System: tert-butyl 2-(4-{[{[2-phenyl-5-(dimethylcarbamoyl)-1,3-oxazol-4-yl]methyl}(furan-2-ylmethyl)amino]methyl}-2,6-dimethylphenoxy)-2-methylpropanoate(1593269-74-9)

Safety Data

• Hazardous Substances Data: 1593269-74-9(Hazardous Substances Data)

Upstream product

• 4620-52-4 Ethyl 4-methyl-2-phenyloxazole-5-carboxylate 
• 1593269-72-7 ethyl 4-{[{4-[(1-tert-butoxy-2-methyl-1-oxopropan-2yl) oxy]-3,5-dimethylbenzyl}(furan-2-ylmethyl) amino] methyl}-2-phenyl-1,3-oxazole-5-carboxylate 
• 189271-78-1 ethyl 4-(bromomethyl)-2-phenyl-1,3-oxazole-5-carboxylate 
• 1593269-73-8 C₃₃H₃₈N₂O₇ 

Downstream Products

• 1593269-84-1 2-(4-{[{[2-phenyl-5-(hydroxymethyl)-1,3-oxazol-4-yl]-methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoic acid 

Relevant articles and documents

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.